RBC Capital Reiterates Outperform on 4D Molecular Therapeutics, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an Outperform rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and maintained a $40 price target.
June 26, 2024 | 3:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating on 4D Molecular Therapeutics and maintained a $40 price target, indicating continued confidence in the company's growth potential.
The reiteration of an Outperform rating and a maintained price target of $40 by RBC Capital suggests strong confidence in 4D Molecular Therapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100